Topics

NICE refuses Keytruda, Inlyta cancer combo

06:45 EST 12 Feb 2020 | PharmaTimes

Despite evidence suggesting that the Keytruda combo would be welcomed by patients, NICE cites uncertainty around the long-term benefit.

Original Article: NICE refuses Keytruda, Inlyta cancer combo

NEXT ARTICLE

More From BioPortfolio on "NICE refuses Keytruda, Inlyta cancer combo"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...